A Diagnostic And Extent Of Disease Multigene Assay For Thyroid Neoplasms

Technology Description

The invention is a diagnostic assay for distinguishing benign from malignant thyroid neoplasms. The assay leverages a panel of differentially expressed biomarkers for diagnosis and to predict disease staging, with utility to complement FNA biopsy of thyroid nodules.

In studies (see below) the multigene assay correctly classified 93% of tumors into the correct risk group (low-risk versus high-risk), with a sensitivity of 78.9% (true positive in high-risk tumors) and specificity of 92% (true negative in low-risk tumors). Positive and negative predictive values were 87.5% and 92%, respectively. 

Looking for Partners

To commercialize the invention

Stage of Development

Preclinical

Related Materials

• A Prospective Study Evaluating the Accuracy of Using Combined Clinical Factors and Candidate Diagnostic Markers to Refine the Accuracy of Thyroid Fine Needle Aspiration Biopsy - 12/01/2010
• Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms - 05/10/2006

Data Availability

Available under CDA

Patent Status